Serial No.: 09/939,769 Attorney Docket No.: 039322-0226

(b) fusing a second nucleic acid fragment into said construct (1), in the same translation reading frame as the first nucleic acid fragment, to yield said first expression vector containing a construct (2) that encodes a chimeric DNA-binding domain/transcription associated biomolecule, wherein said second nucleic acid fragment codes for an antigenic portion of said transcription associated biomolecule that is sufficient to generate antibody capable of binding to said transcription associated biomolecule:

- (c) providing said host cell containing a detectable gene that is under the transcriptional control of the DNA regulatory sequence binding site for said DNA-binding domain peptide;
- (d) cloning a third nucleic acid fragment that codes for a single chain antibody into a second expression vector to yield a construct (3), wherein said single chain antibody is expressed in a bio-active form that may bind to said antigenic portion;
- (e) fusing a fourth nucleic acid fragment that codes for a trans-activation peptide into said construct (3), in the same translation reading frame as the third nucleic acid fragment to yield said expression vector containing a construct (4), encoding a chimeric single chain antibody/trans-activation peptide that may bind to said antigenic portion;
- (f) introducing said first and second expression vectors into said host, such that both vectors are expressed;
- (g) monitoring the expression of said detectable gene, whereby detecting said expression indicates that said fusion reagent does bind said antigenic portion within said host cell upon detection of said expression; and
  - (h) isolating said fusion reagent.

In addition, Applicants noted that there is a minor clerical error in the clean version of pending claims, which is part of the previously filed Supplemental Preliminary Amendment (at page 2). The error is found in claim 1, paragraph (e), line 3, wherein the brackets should be removed.